2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Urogenital Neoplasms
1
Ovarian Neoplasms
1
Ovarian Diseases
1
Ovarian Cysts
1
Neoplasms
1
Gonadal Disorders
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Disease
1
Cysts
1
Adnexal Diseases
1
Interventions
Gemcitabine
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
parathyroid hormone-related peptide (1-36)
2
niraparib
2
Ocoxin
2
Musculoskeletal Manipulations
2
Metformin
2
Clomiphene
2
Cisplatin
2
repotrectinib
1
relacorilant
1
pralsetinib
1
pembrolizumab
1
napabucasin
1
lutetium Lu 177 dotatate
1
fluorodopa F 18
1
copper dotatate CU-64
1
anlotinib
1
adrenosterone
1
Ultrasonography
1
Thalidomide
1
Sunitinib
1
Spironolactone
1
Parathyroid Hormone-Related Protein
1
Parathyroid Hormone
1
Paclitaxel
1
Octreotide
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endocrine System Diseases
×
Diffusion
×
Clear all
NCT02836275
2020-04-14
IOTA-MRI
KU Leuven
Phase NA
Unknown
250 enrolled